Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.

Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC.

Arch Pathol Lab Med. 2006 Jul;130(7):997-1003.

PMID:
16831057
2.

Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.

Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, Hsi ED.

Am J Clin Pathol. 2006 Apr;125(4):625-33.

PMID:
16627272
3.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

4.

Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.

Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, Duyster J, Quintanilla-Martinez L, Fend F.

J Mol Diagn. 2006 Jul;8(3):299-304.

5.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
6.

Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.

Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL.

J Mol Diagn. 2006 Jul;8(3):330-4.

7.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

8.

Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.

Cao HC, Lin J, Qian J, Yao DM, Li Y, Yang J, Chen Q, Chai HY, Xiao GF.

J Clin Lab Anal. 2011;25(4):300-4. doi: 10.1002/jcla.20474.

PMID:
21786333
9.

Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.

Mercier F, Monczak Y, François M, Prchal J, Galipeau J.

Exp Hematol. 2009 Mar;37(3):416-20. doi: 10.1016/j.exphem.2008.11.008. Epub 2009 Jan 9.

PMID:
19135773
10.

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P.

Leukemia. 2006 Jun;20(6):1055-60.

PMID:
16572198
11.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.

Br J Haematol. 2005 Nov;131(3):320-8.

PMID:
16225651
12.

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.

McClure R, Mai M, Lasho T.

Leukemia. 2006 Jan;20(1):168-71. No abstract available.

PMID:
16270039
13.

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC.

Blood. 2006 Aug 15;108(4):1377-80. Epub 2006 May 4.

14.

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.

Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, Guan M.

PLoS One. 2011;6(10):e26534. doi: 10.1371/journal.pone.0026534. Epub 2011 Oct 20.

15.

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M.

Blood. 2006 May 1;107(9):3676-82. Epub 2005 Dec 22.

16.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

17.

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.

Stevenson WS, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg AP, Curtis DJ, Scott HS, Szer J, Alexander WS, Tuckfield A, Roberts AW.

Pathology. 2006 Aug;38(4):336-42.

PMID:
16916724
19.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
20.

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H, MacLeod RA, Zaborski M, Drexler HG.

Leukemia. 2006 Mar;20(3):471-6.

PMID:
16408098

Supplemental Content

Support Center